NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CGEM

Cullinan Therapeutics Inc

Jul 01 • 10:27AM ET

7.46

Dollar change -0.07
Percentage change -0.93	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD INCY JAZZ NVAX KURA EXEL BPMC KPTI ESPR ONCY

| Held by: VTI IWM VXF XBI IWN VTWO SCHA IBB DFAT DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.10	Insider Own	39.13%	Shs Outstand	58.70M	Perf Week	-4.85%
Market Cap	440.25M	Forward P/E	-	EPS next Y	-2.98	Insider Trans	-0.13%	Shs Float	35.92M	Perf Month	-13.71%
Enterprise Value	138.26M	PEG	-	EPS next Q	-0.82	Inst Own	74.01%	Short Float	16.59%	Perf Quarter	-1.45%
Income	-178.74M	P/S	-	EPS this Y	-15.58%	Inst Trans	-0.96%	Short Ratio	13.30	Perf Half Y	-42.17%
Sales	0.00M	P/B	0.79	EPS next Y	7.22%	ROA	-34.74%	Short Interest	5.96M	Perf YTD	-38.75%
Book/sh	9.40	P/C	1.45	EPS next 5Y	0.52%	ROE	-36.57%	52W High	21.01 -64.49%	Perf Year	-56.35%
Cash/sh	5.15	P/FCF	-	EPS past 3/5Y	-28.11% -45.66%	ROIC	-32.36%	52W Low	6.85 8.91%	Perf 3Y	-44.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.55% 5.40%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	1.52%	Oper. Margin	-	ATR (14)	0.43	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.62	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.26	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	11.62	EPS Q/Q	4.67%	SMA20	-10.61%	Beta	-0.08	Target Price	27.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-8.29%	Rel Volume	0.34	Prev Close	7.53
Employees	111	LT Debt/Eq	0.00	Earnings	May 08 BMO	SMA200	-32.98%	Avg Volume	448.13K	Price	7.46
IPO	Jan 08, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.87% -	Trades		Volume	28,798	Change	-0.93%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-25	Resumed	Stifel	Buy	$22
Oct-24-24	Initiated	UBS	Buy	$30
May-01-24	Initiated	Stifel	Buy	$40
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform	$30
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy	$20
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40
Feb-02-21	Initiated	SVB Leerink	Outperform	$52
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight	$38
Feb-02-21	Initiated	Evercore ISI	Outperform	$55
Feb-01-21	Initiated	H.C. Wainwright	Buy	$47

Show Previous Ratings

Jun-05-25 07:31AM	Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal (BioPharma Dive)
Jun-04-25 04:02PM	Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases (GlobeNewswire)
Jun-01-25 08:21AM	Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology (PR Newswire)
May-29-25 07:00AM	Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference (GlobeNewswire) +10.71%
May-22-25 05:15PM	Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 (GlobeNewswire)
07:00AM	Loading…
May-08-25 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 09:55AM	Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know (Zacks)
Apr-29-25 07:00AM	Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sj gren's Disease in the United States (GlobeNewswire)
Apr-23-25 10:14AM	Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 (GlobeNewswire)
Apr-16-25 07:00AM	Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis (GlobeNewswire)
Apr-08-25 10:42AM	Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data (Seeking Alpha)
Feb-27-25 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 07:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-25 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-28-25 07:00PM	Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy (PR Newswire) +7.66%
10:01AM	Loading…
Nov-14-24 10:01AM	Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 (GlobeNewswire)
Nov-07-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.46%
Nov-05-24 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-04-24 07:00AM	Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 (GlobeNewswire)
Oct-16-24 07:00AM	Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus (GlobeNewswire) +8.44%
Sep-17-24 07:00AM	Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
Sep-16-24 07:00AM	Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus (GlobeNewswire) -5.68%
Sep-14-24 04:15AM	Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-03-24 06:26AM	Cullinan Therapeutics announces success for zipalertinib as combo therapy (Clinical Trials Arena)
Jun-01-24 07:00AM	Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib (GlobeNewswire)
May-24-24 08:00AM	Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire) +6.53%
May-23-24 05:04PM	Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 (GlobeNewswire)
May-16-24 12:03PM	HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating (MT Newswires) -10.89%
10:54PM	Loading…
May-15-24 10:54PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 03:09AM	Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ... (GuruFocus.com)
May-01-24 07:05AM	Stifel Initiates Cullinan Oncology With Buy Rating, $40 Price Target (MT Newswires)
Apr-29-24 07:00AM	Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer (GlobeNewswire) +7.19%
Apr-24-24 04:29PM	Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? (Benzinga) +13.32%
10:09AM	Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 (GlobeNewswire)
Apr-16-24 03:32PM	Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity (Benzinga)
07:00AM	Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases (GlobeNewswire)
06:59AM	Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement (GlobeNewswire)
04:48AM	Cullinan changes name, pivots to autoimmune disease (BioPharma Dive)
Mar-16-24 05:31AM	Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
Mar-14-24 12:53PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Feb-27-24 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-02-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-30-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-24-24 07:02PM	Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares (GuruFocus.com)
Dec-18-23 04:53PM	Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.80%
Dec-14-23 04:30PM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines (GlobeNewswire)
Nov-08-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 12:01PM	Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023 (GlobeNewswire) +5.53%
Oct-30-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-06-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 07:00AM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Aug-03-23 04:15PM	REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations (PR Newswire)
Jul-31-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-09-23 04:07PM	Why Shares of Cullinan Oncology Jumped This Week (Motley Fool)
May-25-23 05:00PM	Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023 (GlobeNewswire) +5.13%
May-11-23 04:01PM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 10:08AM	Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023 (GlobeNewswire)
Apr-20-23 07:00AM	Cullinan Oncology to Participate in Stifels 2023 Targeted Oncology Days (GlobeNewswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-27-23 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines (GlobeNewswire)
Mar-14-23 04:35PM	Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-09-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 08:00AM	Cullinan Oncology to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-13-23 07:00PM	Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed (GlobeNewswire)
Feb-02-23 04:01PM	Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-01-23 04:42PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-23 08:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (GlobeNewswire) +5.53%
Jan-23-23 11:07AM	12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds (Insider Monkey)
Jan-03-23 05:13PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-28-22 10:31PM	11 Cheap Value Stocks to Buy According to Seth Klarman (Insider Monkey)
Dec-02-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-22 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 08:00AM	Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors (GlobeNewswire)
Nov-01-22 05:23PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-22 07:00AM	Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619 (GlobeNewswire) +6.03%
Oct-03-22 04:50PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-22 08:00AM	Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference (GlobeNewswire) +5.36%
Sep-01-22 05:27PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-22 04:57PM	Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer (GlobeNewswire)
Aug-10-22 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-01-22 04:55PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.24%
08:00AM	Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference (GlobeNewswire)
Jul-29-22 05:00AM	Why are Massachusetts CEOs paid so much money? Here's a primer (American City Business Journals)
05:00AM	Best bang for the buck: Which CEOs are a bargain for shareholders? (American City Business Journals)
Jul-05-22 04:01PM	Cullinan Oncology to Participate in William Blair Biotech Focus Conference (GlobeNewswire)
Jul-01-22 04:37PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-23-22 08:00AM	Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 (GlobeNewswire)
Jun-01-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.08%
May-31-22 08:00AM	Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting (GlobeNewswire) -6.88%
May-26-22 08:45AM	Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting (GlobeNewswire)
May-19-22 08:00AM	Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) -5.01%
May-16-22 06:45AM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jones Jeffrey Alan	Chief Medical Officer	Feb 25 '25	Sale	8.53	4,895	41,754	174,164	Feb 27 05:00 PM
AHMED NADIM	President and CEO	Feb 25 '25	Sale	8.53	12,529	106,872	430,621	Feb 27 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 25 '25	Sale	8.53	3,756	32,039	142,004	Feb 27 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Feb 25 '25	Sale	8.53	3,756	32,039	136,895	Feb 27 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Jan 06 '25	Sale	12.51	4,000	50,040	95,760	Jan 07 05:00 PM
JENNIFER MICHAELSON	Officer	Jan 06 '25	Proposed Sale	12.68	8,000	101,440		Jan 06 04:22 PM
AHMED NADIM	President and CEO	Dec 24 '24	Sale	11.87	8,400	99,708	263,150	Dec 27 06:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 18 '24	Sale	11.41	4,693	53,547	99,760	Dec 20 05:00 PM
Jones Jeffrey Alan	Chief Medical Officer	Dec 18 '24	Sale	11.41	4,632	52,851	114,059	Dec 20 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Dec 18 '24	Sale	11.41	3,482	39,730	90,651	Dec 20 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 12 '24	Sale	12.52	3,489	43,682	104,453	Dec 16 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Nov 05 '24	Sale	15.64	8,000	125,120	107,942	Nov 07 05:30 PM
Michaelson Jennifer	Chief Scientific Officer	Sep 05 '24	Sale	18.09	8,000	144,720	115,942	Sep 09 05:30 PM
JENNIFER MICHAELSON & MARC D M	Officer	Sep 05 '24	Proposed Sale	18.68	16,000	298,880		Sep 05 04:27 PM
Michaelson Jennifer	Chief Scientific Officer	Jul 05 '24	Sale	16.33	8,000	130,640	123,942	Jul 09 05:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGEM

Cullinan Therapeutics Inc

Upgrade your FINVIZ experience